ORGN granted 180-day Nasdaq cure; must reach $1.00 for 10 days
Rhea-AI Filing Summary
Origin Materials, Inc. received notice from Nasdaq on October 7, 2025 that the exchange has given the company an additional 180-day period, until April 6, 2026, to regain compliance with the Nasdaq Capital Market minimum bid rule. The extension was granted because the company meets Nasdaq's market value of publicly held shares requirement and other initial listing standards, but remains below the $1.00 minimum closing bid threshold. To cure the deficiency the closing bid price must be at least $1.00 per share for 10 consecutive business days within the extension window; the company noted a potential reverse stock split as one remedy. If compliance is not achieved by April 6, 2026, Nasdaq will notify the company of delisting and the company may seek review by a Nasdaq hearings panel, with no assurance of a successful appeal.
Positive
- Nasdaq granted a 180-day extension to regain compliance, not an immediate delisting
- Company meets market-value and other initial listing standards, narrowing the compliance issue to the minimum bid requirement
Negative
- Noncompliance with Nasdaq's Minimum Bid Requirement (closing bid below $1.00)
- Risk of delisting on or after April 6, 2026 if the company fails to achieve a 10-day $1.00 close
- Potential shareholder impact from a reverse stock split if management elects that remedy
Insights
Nasdaq granted a standard 180-day cure period tied to the $1.00 minimum bid rule.
The exchange's notice confirms the company satisfies market-value and other initial-listing requirements but fails the $1.00 minimum closing bid test. The prescribed remedy — achieving a $1.00 close for 10 consecutive business days — is a well-established compliance route and may be achieved by market moves or a reverse stock split.
Key dependencies include share-price action over the next 180 days and any corporate actions to concentrate the float. The practical timeline to watch is through April 6, 2026; failure to clear the test will lead to delisting notice and possible appeal to a hearings panel, which carries execution risk and uncertain outcome.
The company flagged active monitoring and evaluation of options, including a possible reverse split.
Operationally, management must balance market reception, shareholder approval (if required for a reverse split), and timing to create a 10-day streak at or above $1.00. Any reverse split could reduce share count and may affect liquidity and perceptions of dilution.
Concrete near-term items: achieving a sustained closing price at or above $1.00 within the 180-day window to April 6, 2026, or executing a corporate action that achieves equivalent compliance.
FAQ
What did Origin Materials (ORGN) disclose about Nasdaq compliance?
What specific Nasdaq rule must ORGN satisfy to avoid delisting?
What remedies did ORGN mention to regain compliance?
What happens if ORGN does not regain compliance by April 6, 2026?
Does the Nasdaq notice mean ORGN meets all listing requirements?